144 related articles for article (PubMed ID: 23738692)
21. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
22. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
23. New horizons in multiple myeloma therapy.
Santos ES; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
[TBL] [Abstract][Full Text] [Related]
24. Emerging protein kinase inhibitors for the treatment of multiple myeloma.
Lind J; Czernilofsky F; Vallet S; Podar K
Expert Opin Emerg Drugs; 2019 Sep; 24(3):133-152. PubMed ID: 31327278
[No Abstract] [Full Text] [Related]
25. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Hideshima T; Anderson KC
Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
27. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
Vallet S; Podar K
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S35-53. PubMed ID: 23768134
[TBL] [Abstract][Full Text] [Related]
28. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
29. RNA interference for multiple myeloma therapy: targeting signal transduction pathways.
Guo J; McKenna SL; O'Dwyer ME; Cahill MR; O'Driscoll CM
Expert Opin Ther Targets; 2016; 20(1):107-21. PubMed ID: 26190583
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
32. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
33. Promises and challenges of MicroRNA-based treatment of multiple myeloma.
Tagliaferri P; Rossi M; Di Martino MT; Amodio N; Leone E; Gulla A; Neri A; Tassone P
Curr Cancer Drug Targets; 2012 Sep; 12(7):838-46. PubMed ID: 22671926
[TBL] [Abstract][Full Text] [Related]
34. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutic targets for multiple myeloma.
Mahindra A; Cirstea D; Raje N
Future Oncol; 2010 Mar; 6(3):407-18. PubMed ID: 20222797
[TBL] [Abstract][Full Text] [Related]
36. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
[TBL] [Abstract][Full Text] [Related]
37. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
Yap TA; Olmos D; Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
[TBL] [Abstract][Full Text] [Related]
38. Drug insight: thalidomide as a treatment for multiple myeloma.
Kumar S; Anderson KC
Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
40. Selective elimination of leukemia stem cells: hitting a moving target.
Crews LA; Jamieson CH
Cancer Lett; 2013 Sep; 338(1):15-22. PubMed ID: 22906415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
